Aquis AQSE - Delayed Quote GBp

Ananda Pharma Plc (ANA.AQ)

0.3010
-0.0040
(-1.31%)
At close: 2:25:12 PM GMT+1
Loading Chart for ANA.AQ
  • Previous Close 0.3050
  • Open 0.3010
  • Bid --
  • Ask 0.5000 x --
  • Day's Range 0.3010 - 0.3462
  • 52 Week Range 0.2000 - 0.5800
  • Volume 534,489
  • Avg. Volume 926
  • Market Cap (intraday) 12.811M
  • Beta (5Y Monthly) 0.54
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Ananda Pharma Plc, together with its subsidiaries, invests in the medicinal and therapeutic cannabis market in the United Kingdom and internationally. The company provides cannabinoid-based medicines for the treatment of chronic inflammatory pain conditions. It also grows melon and root tubers; develops and distributes health products; wholesales pharmaceutical goods; manufactures and sells organic basic and essential oils; and is involved in crop production activities. The company was formerly known as Ananda Developments Plc and changed its name to Ananda Pharma Plc in December 2024. Ananda Pharma Plc was incorporated in 2018 and is based in London, the United Kingdom.

anandadevelopments.com

12

Full Time Employees

January 31

Fiscal Year Ends

Recent News: ANA.AQ

View More

Performance Overview: ANA.AQ

Trailing total returns as of 5/28/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

ANA.AQ
30.80%
MSCI WORLD (^990100-USD-STRD)
3.85%

1-Year Return

ANA.AQ
33.78%
MSCI WORLD (^990100-USD-STRD)
11.13%

3-Year Return

ANA.AQ
61.16%
MSCI WORLD (^990100-USD-STRD)
37.39%

5-Year Return

ANA.AQ
88.13%
MSCI WORLD (^990100-USD-STRD)
79.23%

Compare To: ANA.AQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ANA.AQ

View More

Valuation Measures

Annual
As of 5/27/2025
  • Market Cap

    13.83M

  • Enterprise Value

    14.47M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    18.11k

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    18.94k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -35.05%

  • Return on Equity (ttm)

    -320.10%

  • Revenue (ttm)

    764

  • Net Income Avi to Common (ttm)

    -6.37M

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    48.02k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: ANA.AQ

View More

Company Insights: ANA.AQ

Research Reports: ANA.AQ

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.